• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Draft Guidance: Re-examined Oncology Protocols Say Maximum Tolerated Dose is Not for Everyone

Draft Guidance: Re-examined Oncology Protocols Say Maximum Tolerated Dose is Not for Everyone

January 23, 2023

Oncology drug trials should consider a wide range of dosages and how they impact a wide variety of participants, rather than immediately titrating patients up to the maximum tolerated dose (MTD), the FDA said in a new draft guidance.

The draft re-examines traditional oncology protocols, which typically attempt to get as many participants as possible to the MTD to balance maximum efficacy with minimum adverse events.

But while that technique may have worked for cytotoxic chemotherapy medications with a steep dose-response curve, it’s not optimal for many new agents, many of which target very specific biomolecular mechanisms. Once these drugs interact with their intended pathways, pushing the dose higher and higher does not necessarily increase benefit — but it does frequently increase the incidence of adverse events (AEs), which can be enough to impact patient quality of life and impair adherence, the agency said.

According to the draft, before launching studies, sponsors need to have various dose strengths available. “Perceived difficulty in manufacturing multiple dose strengths is an insufficient rationale for not comparing multiple dosages in clinical trials,” the guidance said.

Dose-finding trials should also investigate a wide range of doses in as widely varied a population as possible. This should identify any patient characteristics that might significantly affect pharmacokinetics. If there aren’t enough patients, or a wide-enough variety of patients, sponsors can use simulated exposure metrics in these subpopulations.

In addition, adaptive trial designs can be employed to drive patients to one or more dosage arms as interim analyses provide safety and efficacy data. But each dosing arm needs to collect safety and tolerability data, as well as the percentage of dosage interruptions and discontinuations, and these findings should be compared across the arms.

Sponsors should also focus on low-grade AEs as well as more serious problems. Low-grade AEs, like mild-moderate diarrhea, “may still significantly affect a patient’s ability to remain on the drug for extended periods,” the agency says. Patient-reported outcomes are a key way to assess these impacts, and they should be part of every dose-finding study, the guidance says.

Furthermore, dose optimization should be undertaken as part of a drug’s developmental pathway, or in registration trials. Sponsors should “plan their developmental programs such that identification of the optimal dosage can occur prior to or concurrently with the establishment of the drug’s safety and effectiveness,” before submitting a marketing application. Drugs on expedited pathways won’t be exempt from this requirement, the document notes.

The FDA has asked for comments on the draft by March 19.

Read the draft guidance here: https://bit.ly/3XDVyZD.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing